# Clinical Pharmacology Shared Resource

> **NIH NIH P30** · UNIVERSITY OF MINNESOTA · 2022 · $76,084

## Abstract

Clinical Pharmacology Shared Resource Summary
The objective of the Clinical Pharmacology Shared Resource is to advance clinical cancer research by
providing clinical pharmacology services to Masonic Cancer Center (MCC) members. This objective is closely
aligned with the goals of the MCC to translate research findings into safe and highly effective cancer
treatments. In the last CCSG renewal, the Clinical Pharmacology Shared Resource was supported as a
developing shared resource. In this application, it is included as a full shared resource. This Shared Resource
provides 1) drug analysis services and 2) consulting services for pharmacokinetics, pharmacodynamics, and
pharmacogenetics.
The Clinical Pharmacology Shared Resource is affiliated with and benefits from the diverse research foci of the
Department of Experimental and Clinical Pharmacology in the College of Pharmacy' Clinical Pharmacology
Analytical Laboratory (CPAL). The MCC's Clinical Pharmacology Shared Resource is led by Associate
Professor, Mark Kirstein, PharmD, who oversees the laboratory and provides the consulting services, and has
been an MCC member for over 15 years. Personnel in the CPAL develop and validate assays to measure drug
and metabolite concentrations using HPLC, GC-MS, and LC-MS/MS and to assure accurate measurement
across broad ranges of concentrations. The Shared Resource processes, stores, and ships samples for local
and national pharmacology studies. Dr. Kirstein provides consulting services to support the design, conduct,
and analysis of clinical pharmacology studies and conducts pharmacokinetic, pharmacodynamic, and
pharmacogenetic analyses.
These services are highly cost efficient because most clinical investigators cannot afford to purchase the
expensive analytical equipment needed for drug analysis, may not have laboratory staff trained in assay
development and validation, and in some cases may not have laboratories that can process and store blood
samples for pharmacokinetic or pharmacodynamic studies. In addition, most clinical investigators do not have
the expertise to conduct pharmacokinetic analyses or the financial resources to hire out these analyses.
Therefore the Clinical Pharmacology Shared Resource is providing important, accessible, and value-added
services to MCC members.
Under the leadership of Dr. Kirstein, the Shared Resource has consulted on and supported studies led by MCC
researchers and developed assays to detect more than a dozen cancer drugs and their metabolites. Dr.
Kirstein has extensive research experience in clinical pharmacology, with expertise in oncology. Day-to-day
operations of the CPAL are overseen by Mr. James Fisher, who has 32 years of analytical experience and has
managed the Laboratory since 2003. As a result of its robust support and services, use and recognition of the
Clinical Pharmacology Shared Resource have increased among MCC members in the previous period.

## Key facts

- **NIH application ID:** 10333239
- **Project number:** 5P30CA077598-24
- **Recipient organization:** UNIVERSITY OF MINNESOTA
- **Principal Investigator:** MARK N KIRSTEIN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $76,084
- **Award type:** 5
- **Project period:** 1998-06-01 → 2024-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10333239

## Citation

> US National Institutes of Health, RePORTER application 10333239, Clinical Pharmacology Shared Resource (5P30CA077598-24). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10333239. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*